

VU Research Portal

Optimalisation of conventional therapies in inflammatory bowel disease

Seinen, M.L.

2016

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Seinen, M. L. (2016). *Optimalisation of conventional therapies in inflammatory bowel disease: Old wine in new bottles*. [, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

PART I INTRODUCTION

- Chapter 1** Introduction and outline of this thesis
- Chapter 2** Thiopurine therapy in inflammatory bowel disease patients:
analyses of two 8-year intercept cohorts

PART II OPTIMALISATION OF CONVENTIONAL THERAPIES

- Chapter 3** Routinely established skewed thiopurine metabolism leads to a striking
high rate of early therapeutic failure in patients with inflammatory bowel
disease
- Chapter 4** High TPMT activity as a risk factor for severe myelosuppression during
thiopurine therapy
- Chapter 5** Safety and effectiveness of long-term allopurinol-thiopurine
maintenance treatment in inflammatory bowel disease
- Chapter 6** The effect of allopurinol and low-dose thiopurine combination therapy
on the activity of three pivotal thiopurine metabolizing enzymes: results
from a prospective pharmacological study
- Chapter 7** Safe use of allopurinol and low dose mercaptopurine during pregnancy
in an ulcerative colitis patient
- Chapter 8** Nodular regenerative hyperplasia of the liver in IBD patients treated
with allopurinol-thiopurine combination therapy
- Chapter 9** Allopurinol-thiopurine combination therapy in inflammatory bowel
disease
- Chapter 10** Hepatotoxicity associated with 6-methyl mercaptopurine formation
during azathioprine and mercaptopurine therapy does not occur on the
short-term during tioguanine therapy in inflammatory bowel disease
treatment
- Chapter 11** Sustained clinical benefit and tolerability of methotrexate
monotherapy following thiopurine therapy in patients with Crohn's
disease

PART III PHARMACODYNAMIC MONITORING

Chapter 12 Rac1 a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease

Chapter 13 Rac attack; modulation of the small GTPase Rac in inflammatory bowel disease and thiopurine therapy

PART IV DISCUSSION

Chapter 14 Summary, general discussion, implications for daily clinical practice and future perspectives and challenges

Chapter 15 Dutch summary

PART V APPENDICES

Appendix I Dosing tioguanine in inflammatory bowel disease; expert based guideline for daily practice

Appendix II List of abbreviations

Appendix III Authors and affiliations

Appendix IV List of publications

Appendix V Acknowledgement/ Dankwoord

Appendix VI About the author